Abstract
The antitumor activity of dihydrohomofolate against L1210 and L1210/FR-8 leukemia was studied and found to be comparable to that of tetrahydrohomofolate. Pretreatment of mice with methotrexate. a potent inhibitor of dihydrofolate reductase, decreased the antitumor activity of reduced homofolates against L1210/FR-8 indicating that an adequate level of free enzyme is probably necessary for the antitumor activity. The reduced homofolates were found to be less effective against L1210 than against L1210/FR-8, however, the antitumor activity became comparable when mice were kept on a folate-deficient diet. This suggests that factors other than tissue levels of dihydrofolate reductase could influence the response of tumors to reduced homofolates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
